New investigations into retatrutide, a dual activator for GLP-1 and GIP receptors, are showing encouraging results in treating excess mass and related 2 diabetes. Preclinical evidence suggest a novel action https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/